Novo is a Buy Right Now
The Label is the Moat
This will be a "best ideas only" bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.
This will be a quick note as I recently read Left’s post on the new Wegovy label and then I looked at the stock chart. Everyone decided Lilly won the GLP-1 wars sometime around mid-2024 (hence why the stock is down ~60%) but I'll keep it short on why that conclusion is premature, and why the inflection is happening right now.